Profile data is unavailable for this security.
About the company
Medifast, Inc. is a health and wellness company. The Company provides a habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a comprehensive approach to help them achieve lasting optimal health and wellbeing. OPTAVIA's lifestyle plans deliver clinically proven health benefits as well as evidence-based tools, including scientifically developed products and a framework for habit creation reinforced by independent coaches and community support. Through a collaboration with the virtual primary care provider LifeMD, Inc (LifeMD), OPTAVIA customers have access to board-certified affiliated clinicians and medications, such as GLP-1s, that support treatment plans for obesity and other health conditions. OPTAVIA Coaches introduce customers to a set of healthy habits, and offer OPTAVIA-branded products, including Fuelings as well as OPTAVIA ACTIVE, a line of essential amino acid supplements and protein powders. Its operations are conducted through its subsidiaries.
- Revenue in USD (TTM)1.07bn
- Net income in USD99.41m
- Incorporated1989
- Employees634.00
- LocationMedifast Inc11445 Cronhill DrOWINGS MILLS 21117-2270United StatesUSA
- Phone+1 (732) 764-0619
- Fax+1 (410) 581-8070
- Websitehttps://medifastinc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rani Therapeutics Holdings Inc | 0.00 | -33.97m | 352.40m | 140.00 | -- | 25.62 | -- | -- | -1.33 | -1.33 | 0.00 | 0.2729 | 0.00 | -- | -- | 0.00 | -81.81 | -- | -131.29 | -- | -- | -- | -- | -- | -- | -37.05 | 0.5359 | -- | -- | -- | -11.06 | -- | -- | -- |
| Precigen Inc | 6.23m | -95.90m | 353.47m | 202.00 | -- | 2.98 | -- | 56.78 | -0.3933 | -0.3933 | 0.0255 | 0.476 | 0.0339 | -- | 6.62 | 30,816.83 | -52.26 | -31.50 | -72.27 | -38.63 | 1.70 | 44.00 | -1,540.63 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 360.61m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Amarin Corporation plc (ADR) | 306.91m | -59.11m | 360.82m | 275.00 | -- | 0.6506 | -- | 1.18 | -0.145 | -0.145 | 0.7529 | 1.35 | 0.3573 | 0.4192 | 2.32 | 1,116,040.00 | -6.88 | -4.48 | -9.86 | -6.54 | 66.72 | 75.70 | -19.26 | -8.59 | 1.80 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Harrow Inc | 130.19m | -24.41m | 363.17m | 315.00 | -- | 5.10 | -- | 2.79 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Medifast Inc | 1.07bn | 99.41m | 365.77m | 634.00 | 3.69 | 1.82 | 3.25 | 0.3412 | 9.11 | 9.11 | 98.22 | 18.49 | 3.42 | 3.42 | 245.69 | 1,690,939.00 | 31.76 | 41.25 | 50.60 | 69.38 | 72.37 | 73.20 | 9.27 | 10.06 | 1.84 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
| Nature's Sunshine Products Inc | 445.32m | 15.08m | 367.35m | 814.00 | 25.30 | 2.39 | 13.01 | 0.8249 | 0.7715 | 0.7715 | 22.78 | 8.16 | 1.86 | 1.84 | 38.84 | 547,076.20 | 6.85 | 6.57 | 10.02 | 9.41 | 72.11 | 72.69 | 3.69 | 3.74 | 1.29 | -- | 0.00 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| Cartesian Therapeutics Inc | 26.00m | -219.71m | 368.40m | 38.00 | -- | -- | -- | 14.17 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Tscan Therapeutics Inc | 21.05m | -89.22m | 371.23m | 154.00 | -- | 2.34 | -- | 17.64 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Revance Therapeutics Inc | 234.04m | -323.99m | 372.05m | 534.00 | -- | -- | -- | 1.59 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -44.60m | 373.43m | 19.00 | -- | -- | -- | -- | -10.38 | -10.38 | 0.00 | -1.56 | 0.00 | -- | -- | 0.00 | -94.31 | -86.84 | -178.23 | -130.46 | -- | -- | -- | -769.76 | -- | -15.46 | 1.74 | -- | -- | -- | -5.33 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -19.06m | 376.92m | 10.00 | -- | 300.04 | -- | -- | -0.9149 | -0.9149 | 0.00 | 0.0384 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -60.47 | 0.1012 | -- | -- | -- | -272.15 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 170.28m | -225.25m | 377.24m | 709.00 | -- | 1.22 | -- | 2.22 | -1.56 | -1.56 | 1.18 | 2.13 | 0.2244 | 5.23 | 4.36 | 240,163.60 | -29.69 | -19.69 | -34.13 | -22.06 | 55.63 | 67.18 | -132.32 | -122.27 | 4.50 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Cibus Inc | 1.82m | -267.63m | 377.92m | 183.00 | -- | 1.07 | -- | 207.99 | -22.63 | -22.63 | 0.1769 | 14.27 | 0.0064 | -- | -- | 9,928.96 | -119.13 | -86.28 | -135.32 | -96.45 | 2.31 | -- | -18,582.22 | -792.07 | -- | -3.70 | 0.0049 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| iTeos Therapeutics Inc | 12.60m | -112.64m | 378.86m | 157.00 | -- | 0.6585 | -- | 30.08 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Anika Therapeutics Inc | 166.66m | -82.67m | 379.20m | 357.00 | -- | 1.79 | -- | 2.28 | -5.64 | -5.64 | 11.37 | 14.48 | 0.5378 | 1.48 | 4.72 | 466,840.30 | -26.68 | -5.41 | -29.48 | -5.87 | 61.85 | 60.70 | -49.60 | -12.60 | 3.76 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
Data as of Apr 25 2024. Currency figures normalised to Medifast Inc's reporting currency: US Dollar USD
58.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.66m | 15.20% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.65m | 15.16% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 757.61k | 6.95% |
| Pacer Advisors, Inc.as of 31 Dec 2023 | 522.73k | 4.80% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 427.48k | 3.92% |
| First Trust Advisors LPas of 31 Dec 2023 | 397.44k | 3.65% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 310.56k | 2.85% |
| Geode Capital Management LLCas of 31 Dec 2023 | 246.82k | 2.27% |
| Citadel Advisors LLCas of 31 Dec 2023 | 232.15k | 2.13% |
| Numeric Investors LLCas of 31 Dec 2023 | 216.56k | 1.99% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
